Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress

Prostate cancers (PCs) with loss of the potent tumor suppressors TP53 and RB1 exhibit poor outcomes. TP53 and RB1 also influence cell plasticity and are frequently lost in PCs with neuroendocrine (NE) differentiation. Therapeutic strategies that address these aggressive variant PCs are urgently need...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cell Rep
Hlavní autoři: Nyquist, Michael D., Corella, Alexandra, Coleman, Ilsa, De Sarkar, Navonil, Kaipainen, Arja, Ha, Gavin, Gulati, Roman, Ang, Lisa, Chatterjee, Payel, Lucas, Jared, Pritchard, Colin, Risbridger, Gail, Isaacs, John, Montgomery, Bruce, Morrissey, Colm, Corey, Eva, Nelson, Peter S.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7453577/
https://ncbi.nlm.nih.gov/pubmed/32460015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2020.107669
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky